The pharmaceutical sector is regularly under the scrutiny of competition authorities throughout Europe. In keeping with this trend, the past 18 months saw notable developments in pay-for-delay and excessive pricing cases, as well as on market definition and lifecycle management practices.
In this article, Dechert antitrust/competition attorneys Mélanie Thill-Tayara and Marion Provost describe the most recent developments in the sector, focusing on cases involving alleged abuses of dominant position.
Read "Dominance in the Pharmaceutical Sector: An Overview of EU and National Case Law."
Related Professionals
